SSTR2 and neoplasm: To verify the therapeutic effects of targeting SSTR2 with 177Lu-DOTA-TATE, we treated CHLA-15 tumor-bearing mice with 177Lu-DOTA-TATE at the dose of 20 MBq/animal.